SCYNEXIS to Report Fourth Quarter and Full Year 2021 Financial Results and Provide a Business Update
SCYNEXIS, Inc. (NASDAQ: SCYX) will announce its fourth quarter and full year 2021 financial results on March 29, 2022. The company, dedicated to developing innovative medicines for difficult-to-treat infections, plans to hold a conference call at 8:30 a.m. EDT to discuss the results. SCYNEXIS's lead product, ibrexafungerp, is a systemic antifungal approved by the FDA on June 1, 2021, and is set for launch in the U.S. as BREXAFEMME. The company is continuing investigations into ibrexafungerp for other significant fungal infections.
- FDA approval of BREXAFEMME enhances market potential.
- Ongoing investigations into ibrexafungerp for critical infections could expand product offerings.
- None.
JERSEY CITY, N.J., March 24, 2022 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant infections, will announce fourth quarter and full year 2021 financial results and provide a business update on Tuesday, March 29, 2022. The company will host a conference call and webcast at 8:30 a.m. Eastern Daylight Time on the same day.
Investors (domestic): (877) 705-6003
Investors (international): (201) 493-6725
Webcast: https://viavid.webcasts.com/starthere.jsp?ei=1531381&tp_key=627476145d
Conference ID: 13727358
A recording of the webcast will be posted on the Company’s website, www.scynexis.com, following the event.
About SCYNEXIS
SCYNEXIS, Inc. (NASDAQ: SCYX) is a biotechnology company pioneering innovative medicines to help millions of patients worldwide overcome and prevent difficult-to-treat infections that are becoming increasingly drug-resistant. SCYNEXIS scientists are developing the company’s lead asset, ibrexafungerp (formerly known as SCY-078), as a broad-spectrum, systemic antifungal for multiple fungal indications in both the community and hospital settings. SCYNEXIS has initiated the launch of its first commercial product in the U.S., BREXAFEMME® (ibrexafungerp tablets). The U.S. Food and Drug Administration (FDA) approved BREXAFEMME on June 1, 2021. In addition, investigation and development of ibrexafungerp for the prevention of recurrent Vulvovaginal Candidiasis (VVC) and the treatment of life-threatening invasive fungal infections in hospitalized patients is ongoing. For more information, visit www.scynexis.com.
CONTACT:
Investor Relations
Irina Koffler
LifeSci Advisors
Tel: (646) 970-4681
ikoffler@lifesciadvisors.com
Media Relations
Gloria Gasaatura
LifeSci Communications
Tel: (646) 970-4688
Ggasaatura@lifescicomms.com
FAQ
When will SCYNEXIS announce its financial results?
What is BREXAFEMME?
What time is the SCYNEXIS conference call?
